Unmet Need: Alternative avenues for patients insensitive to existing cancer immunotherapies. To date, no therapies have been developed to specifically target these CD28-CD8+ T-cells to treat cancer. This technology is a cancer immunotherapy platform that activates CD28-CD8+ T-cells via the CD58:CD2 axis.
This technology is an engineered probiotic bacteria-guided CAR-T immunotherapy system for the treatment of various types of cancer, including solid tumors. Unmet Need: Effective immunotherapy for solid tumors. Solid tumors have an especially low immunotherapy response rate, hindering the use of immunotherapy in patients with certain types of cancer.
This highly specified method of targeted antibody crosslinking avoids the side effects of conventional bispecific antibody-based immunotherapy. Current treatments for cancer and immunological disease often lead to damage of healthy subpopulations of cells that share cell-surface markers with the diseased cells. The Technology: Therapeutic platform using customizable antibody pairs for cancer immunotherapy.
Applications:
Immunotherapy for the treatment of cancer. Unmet Need: Precise immunotherapies for treating cancer. This technology is a recombinant protein-induced antibody collection against Immunoglobulin-Like Transcript 3 (ILT3) that can modulate cancer cell growth and induce immune checkpoint blockade.
Immune checkpoint inhibitors, such as anti-PD-1 therapies, have transformed therapeutic outcomes in cancers such as melanoma and lung cancer. Self-Renewing CD8+ T-Cell Abundance in Blood Associates with Response to Immunotherapy. Unmet Need: Improved tumor response during immunotherapy treatments.
Therapeutics for cancers inhibiting progression to advanced stages. This technology uses computational methods to identify the cell of origin and differentiation path leading to the formation of a particular type of cancer-associated fibroblasts (“aCAFs,” standing for aggressive cancer-associated fibroblasts), as well as related pan-cancer targets for therapeutic development. This technology uses computational methods to identify the cell of origin and differentiation path leading to the formation of a particular type of cancer-associated fibroblasts (“aCAFs,” standing for aggressive cancer-associated fibroblasts), as well as related pan-cancer targets for therapeutic development.
Applications:
Immunotherapy for cancer and neuroinflammatory and neurogenerative diseases. Studying the pathways through which dsRNAs can trigger neuroinflammation can identify therapeutic targets for neuroinflammatory diseases, as well as cancer immunotherapies. Immunomodulation via the modification of the length of 3’ UTRs can be used to develop therapies for neurodegenerative and neuroinflammatory diseases as well as cancer immunotherapies.
This technology is a set of master regulators of tumor regulatory T cell infiltration that can be targeted for cancer treatment. Applications:
Immunotherapy for cancer treatment. Current immunopharmacological cancer treatments target receptors and cytokines that affect both peripheral and tumor infiltrating immune cells.
Radiotherapy for cancer treatment. Research tool for study and development of cancer vaccines. As adenosine signaling is a conserved signaling pathway, further study of its relationship with immune signaling and the tumor microenvironment may identify potential therapeutic targets across multiple cancers.